- Home
- ODYS vs IMUX Comparison
ODYS vs IMUX Comparison
Compare ODYS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- IMUX
- Stock Information
- Founded
- ODYS N/A
- IMUX 2016
- Country
- ODYS Israel
- IMUX United States
- Employees
- ODYS N/A
- IMUX N/A
- Industry
- ODYS
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ODYS
- IMUX Health Care
- Exchange
- ODYS NYSE
- IMUX Nasdaq
- Market Cap
- ODYS 107.4M
- IMUX 102.2M
- IPO Year
- ODYS N/A
- IMUX N/A
- Fundamental
- Price
- ODYS $6.66
- IMUX $1.10
- Analyst Decision
- ODYS
- IMUX Strong Buy
- Analyst Count
- ODYS 0
- IMUX 7
- Target Price
- ODYS N/A
- IMUX $12.67
- AVG Volume (30 Days)
- ODYS 20.4K
- IMUX 555.7K
- Earning Date
- ODYS 03-28-2025
- IMUX 05-07-2025
- Dividend Yield
- ODYS N/A
- IMUX N/A
- EPS Growth
- ODYS N/A
- IMUX N/A
- EPS
- ODYS N/A
- IMUX N/A
- Revenue
- ODYS $3,964,000.00
- IMUX N/A
- Revenue This Year
- ODYS N/A
- IMUX N/A
- Revenue Next Year
- ODYS N/A
- IMUX N/A
- P/E Ratio
- ODYS N/A
- IMUX N/A
- Revenue Growth
- ODYS 30.70
- IMUX N/A
- 52 Week Low
- ODYS $5.01
- IMUX $0.92
- 52 Week High
- ODYS $10.80
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- IMUX 46.81
- Support Level
- ODYS N/A
- IMUX $1.18
- Resistance Level
- ODYS N/A
- IMUX $1.28
- Average True Range (ATR)
- ODYS 0.00
- IMUX 0.07
- MACD
- ODYS 0.00
- IMUX -0.00
- Stochastic Oscillator
- ODYS 0.00
- IMUX 6.00
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.